Skip to main content
Top

2014 | OriginalPaper | Hoofdstuk

10. Mammacarcinoom

Auteurs : Rhodé Bijlsma, Elsken van der Wall, Arjen Witkamp

Gepubliceerd in: Ontwikkelingen in de oncologie

Uitgeverij: Bohn Stafleu van Loghum

share
DELEN

Deel dit onderdeel of sectie (kopieer de link)

  • Optie A:
    Klik op de rechtermuisknop op de link en selecteer de optie “linkadres kopiëren”
  • Optie B:
    Deel de link per e-mail

Inleiding

Borstkanker heeft longkanker van de eerste plaats verdrongen en is nu de meest voorkomende vorm van kanker in Nederland. Eén op de acht in Nederland geboren vrouwen krijgt in de loop van haar leven borstkanker (zie figuur 10.1). De diagnose werd in 2009 bij 13.500 vrouwen gesteld en de incidentie stijgt nog steeds: naar verwachting zullen het er in 2017 meer dan 17.000 zijn.1 Borstkanker komt overwegend, maar niet uitsluitend bij vrouwen voor. In 2009 kregen 100 mannen borstkanker en ook bij hen stijgt de incidentie, zij het minder snel dan bij vrouwen. Jaarlijks zullen er in de gemiddelde huisartsenpraktijk één à twee nieuwe borstkankerpatiënten bijkomen.2 Met deze cijfers behoort Nederland tot de koplopers binnen Europa. Wat hiervan de precieze oorzaak is, is niet geheel duidelijk. Wel zijn er een aantal risicofactoren, zoals het weinig en op relatief late leeftijd krijgen van kinderen en het kort of niet geven van borstvoeding. Ook overmatig alcoholgebruik, overgewicht en gebrek aan lichaamsbeweging spelen een rol.3-5 In 5 tot 10% van de gevallen betreft het een erfelijke vorm van borstkanker.
Literatuur
2.
go back to reference Schulkens-van den Pol JA, Kaas R. Borstkanker, behandeling en zorg. Maarssen: Elsevier Gezondheidszorg, 2006. Schulkens-van den Pol JA, Kaas R. Borstkanker, behandeling en zorg. Maarssen: Elsevier Gezondheidszorg, 2006.
3.
go back to reference Dumitrescu RG, Cotarla I. Understanding breast cancer risk: Where do we stand in 2005? J Cell Mol Med 2005;9:208–21.PubMedCrossRef Dumitrescu RG, Cotarla I. Understanding breast cancer risk: Where do we stand in 2005? J Cell Mol Med 2005;9:208–21.PubMedCrossRef
5.
go back to reference Morrow M. Identification of the woman at risk for breast cancer: Problem solved? Recent Results Cancer Res 1999;151:85–95.PubMedCrossRef Morrow M. Identification of the woman at risk for breast cancer: Problem solved? Recent Results Cancer Res 1999;151:85–95.PubMedCrossRef
6.
go back to reference Cardoso F, Van’t Veer L, Rutgers E, Lois S, Mook S, Piccart-Gebhart MJ. Clinical application of the 70-gene profile: The MINDACT trial. J Clin Oncol 2008;26:729–35.PubMedCrossRef Cardoso F, Van’t Veer L, Rutgers E, Lois S, Mook S, Piccart-Gebhart MJ. Clinical application of the 70-gene profile: The MINDACT trial. J Clin Oncol 2008;26:729–35.PubMedCrossRef
7.
go back to reference Bartelink H, Horiot JC, Poortmans PM, Struikmans H, Van den Bogaert W, Fourquet A, et al. Impact of a higher radiation dose on local control and survival in breast-conserving therapy of early breast cancer: 10-year results of the randomized boost versus no boost EORTC 22881-10882 trial. J Clin Oncol 2007;25:3259–65.PubMedCrossRef Bartelink H, Horiot JC, Poortmans PM, Struikmans H, Van den Bogaert W, Fourquet A, et al. Impact of a higher radiation dose on local control and survival in breast-conserving therapy of early breast cancer: 10-year results of the randomized boost versus no boost EORTC 22881-10882 trial. J Clin Oncol 2007;25:3259–65.PubMedCrossRef
8.
go back to reference Rutgers EJ, Meijnen P, Bonnefoi H. Clinical trials update of the European Organization for Research and Treatment of Cancer Breast Cancer Group. Breast Cancer Res 2004;6:165–9.PubMedCentralPubMedCrossRef Rutgers EJ, Meijnen P, Bonnefoi H. Clinical trials update of the European Organization for Research and Treatment of Cancer Breast Cancer Group. Breast Cancer Res 2004;6:165–9.PubMedCentralPubMedCrossRef
9.
go back to reference Bilimoria KY, Bentrem DJ, Hansen NM, Bethke KP, Rademaker AW, K CY, et al. Comparison of sentinel lymph node biopsy alone and completion axillary lymph node dissection for node-positive breast cancer. J Clin Oncol 2009;27:2946–53.PubMedCrossRef Bilimoria KY, Bentrem DJ, Hansen NM, Bethke KP, Rademaker AW, K CY, et al. Comparison of sentinel lymph node biopsy alone and completion axillary lymph node dissection for node-positive breast cancer. J Clin Oncol 2009;27:2946–53.PubMedCrossRef
10.
go back to reference Giuliano AE, Hunt KK, Ballman KV, Beitsch PD, Withworht PW, Blumencranz PW, et al. Axillary dissection vs no axillary dissection in women with invasive breast cancer and sentinel node metastasis: A randomized clinical trail. JAMA 2011;305:569–75.PubMedCrossRef Giuliano AE, Hunt KK, Ballman KV, Beitsch PD, Withworht PW, Blumencranz PW, et al. Axillary dissection vs no axillary dissection in women with invasive breast cancer and sentinel node metastasis: A randomized clinical trail. JAMA 2011;305:569–75.PubMedCrossRef
11.
go back to reference Zhao Z, Wu F. Minimally-invasive thermal ablation of early-stage breast cancer: A systemic review. Eur J Surg Oncol 2010;36:1149–55.PubMedCrossRef Zhao Z, Wu F. Minimally-invasive thermal ablation of early-stage breast cancer: A systemic review. Eur J Surg Oncol 2010;36:1149–55.PubMedCrossRef
12.
go back to reference Early Breast Cancer Trialists’ Collaborative Group (EBCTCG). Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: An overview of the randomised trials. Lancet 2005;365:1687–717. Early Breast Cancer Trialists’ Collaborative Group (EBCTCG). Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: An overview of the randomised trials. Lancet 2005;365:1687–717.
13.
go back to reference Baselga J. Monoclonal antibodies directed at growth factor receptors. Ann Oncol 2000;11:187–90.PubMed Baselga J. Monoclonal antibodies directed at growth factor receptors. Ann Oncol 2000;11:187–90.PubMed
14.
go back to reference Goldenberg MM. Trastuzumab, a recombinant DNA-derived humanized monoclonal antibody, a novel agent for the treatment of metastatic breast cancer. Clin Ther 1999;21:309–18.PubMedCrossRef Goldenberg MM. Trastuzumab, a recombinant DNA-derived humanized monoclonal antibody, a novel agent for the treatment of metastatic breast cancer. Clin Ther 1999;21:309–18.PubMedCrossRef
15.
go back to reference Joensuu H, Bono P, Kataja V, Alanko T, Kokko R, Asola R, et al. Fluorouracil, epirubicin, and cyclophosphamide with either docetaxel or vinorelbine, with or without trastuzumab, as adjuvant treatments of breast cancer: Final results of the FinHer Trial. J Clin Oncol 2009;27:5685–92.PubMedCrossRef Joensuu H, Bono P, Kataja V, Alanko T, Kokko R, Asola R, et al. Fluorouracil, epirubicin, and cyclophosphamide with either docetaxel or vinorelbine, with or without trastuzumab, as adjuvant treatments of breast cancer: Final results of the FinHer Trial. J Clin Oncol 2009;27:5685–92.PubMedCrossRef
16.
go back to reference Miller K, Wang M, Gralow J, Dickler M, Cobleigh M, Perez EA, et al. Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancer. N Engl J Med 2007;357:2666–76.PubMedCrossRef Miller K, Wang M, Gralow J, Dickler M, Cobleigh M, Perez EA, et al. Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancer. N Engl J Med 2007;357:2666–76.PubMedCrossRef
17.
go back to reference Comen EA, Robson M. Poly(ADP-ribose) polymerase inhibitors in triple-negative breast cancer. Cancer J 2010;16:48–52.PubMedCrossRef Comen EA, Robson M. Poly(ADP-ribose) polymerase inhibitors in triple-negative breast cancer. Cancer J 2010;16:48–52.PubMedCrossRef
18.
go back to reference Baselga J, Campone M, Piccart M, Burris HA 3rd, Rugo HS, Sahmoud T, et al. Everolimus in postmenopausal hormone-receptor-positive advanced breast cancer. N Engl J Med 2012;366:520–9.PubMedCrossRef Baselga J, Campone M, Piccart M, Burris HA 3rd, Rugo HS, Sahmoud T, et al. Everolimus in postmenopausal hormone-receptor-positive advanced breast cancer. N Engl J Med 2012;366:520–9.PubMedCrossRef
Metagegevens
Titel
Mammacarcinoom
Auteurs
Rhodé Bijlsma
Elsken van der Wall
Arjen Witkamp
Copyright
2014
Uitgeverij
Bohn Stafleu van Loghum
DOI
https://doi.org/10.1007/978-90-368-0436-3_10